A5041455719- Prostate Cancer Treatment and Research
- Advanced Radiotherapy Techniques
- Prostate Cancer Diagnosis and Treatment
- Effects of Radiation Exposure
- Radiopharmaceutical Chemistry and Applications
- Advances in Oncology and Radiotherapy
- Gastric Cancer Management and Outcomes
- Lung Cancer Diagnosis and Treatment
- Genetic factors in colorectal cancer
- BRCA gene mutations in cancer
- Genetic and Clinical Aspects of Sex Determination and Chromosomal Abnormalities
- Cancer-related molecular mechanisms research
- Genetic Associations and Epidemiology
- Medical Imaging Techniques and Applications
- Colorectal Cancer Treatments and Studies
- Colorectal Cancer Surgical Treatments
- Cancer, Lipids, and Metabolism
- Global Cancer Incidence and Screening
- Hepatocellular Carcinoma Treatment and Prognosis
- Molecular Biology Techniques and Applications
- Radiation Therapy and Dosimetry
- Colorectal and Anal Carcinomas
- Korean Peninsula Historical and Political Studies
- Inflammatory Bowel Disease
- Intraperitoneal and Appendiceal Malignancies
Complejo Hospitalario Universitario de Santiago
2013-2025
Servicio Gallego de Salud
2011-2025
Universidade de Santiago de Compostela
2025
Instituto de Investigación Sanitaria de Santiago
2023-2025
Complexo Hospitalario Universitario A Coruña
2011-2023
Abstract Background A total of 10%–20% patients develop long-term toxicity following radiotherapy for prostate cancer. Identification common genetic variants associated with susceptibility to radiotoxicity might improve risk prediction and inform functional mechanistic studies. Methods We conducted an individual patient data meta-analysis six genome-wide association studies (n = 3871) in men European ancestry who underwent Radiotoxicities (increased urinary frequency, decreased stream,...
REQUITE aimed to establish a resource for multi-national validation of models and biomarkers that predict risk late toxicity following radiotherapy. The purpose this article is provide summary descriptive data.
Abstract Background: Late bladder toxicity is a concern for patients receiving prostate cancer radiotherapy and negatively impacts survivors. Few risk factors are known beyond the radiation dose volume of exposed. A polygenic score (PRS) could identify susceptible patients. Methods: PRS was built using genome-wide association results from Radiogenomics Consortium (N=3,988), then tested in prospective REQUITE URWCI studies (N=2,034). The primary outcome time-to-patient-reported gross (≥ grade...
Prostate cancer is the second most common globally, with radiation therapy (RT) being a key treatment for clinically localized and locally advanced cases. Given high survival rates, addressing long-term side effects of RT crucial preserving quality-of-life. Radiogenomics, study genetic variations affecting response to radiation, has primarily focussed on genomic biomarkers, while DNA methylation studies offer insights into responses. Although research centred tumours, no epigenome-wide...
e16530 Background: Changes in PSA are widely used as a biomarker for the monitoring of treatment outcome Metastatic Castration-Resistant Prostate Cancer (mCRPC) clinical real-world setting. Early changes (before 12 weeks) not considered definition Progression (PSAProg) due to potential spurious “flare” reactions. We aimed evaluate significance an early increase Abiraterone/Enzalutamide (Abi/Enz)-treated mCRPC patients (pts). Methods: retrospectively evaluated Abi/Enz-treated pts from 11...